[A19-103] Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55
Last updated 06.03.2020
Project no.:
A19-103
Commission:
Commission awarded on 09.12.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Adults with HIV-1 infection whose virus has no known or suspected resistance to integrase inhibitors or lamivudine
Now hint of lesser benefit in comparison with continuation of ongoing therapy for pretreated adults with HIV-1 infection without indication for a treatment switch (before: added benefit not proven)
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-102 | Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55 | Commission completed |
| A19-55 | Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-02-06 A G-BA decision was published.